Stiripentol identifies a therapeutic target to reduce oxaluria.
Letavernier E, Daudon M.
Curr Opin Nephrol Hypertens. 2020 Jul;29(4):394-399. doi: 10.1097/MNH.0000000000000621.
Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M.
Am J Kidney Dis. 2022 May;79(5):717-727. doi: 10.1053/j.ajkd.2021.07.018. Epub 2021 Sep 9.
Primary Hyperoxaluria.
Xie X, Zhang X.
N Engl J Med. 2022 Mar 10;386(10):976. doi: 10.1056/NEJMicm2113369. Epub 2022 Mar 5.
Primary hyperoxaluria.
Cochat P, Rumsby G.
N Engl J Med. 2013 Aug 15;369(7):649-58. doi: 10.1056/NEJMra1301564.
Oxalate Maculopathy.
Kourti P, Gonzalez-Martin J, Yeo DCM.
Ophthalmol Retina. 2020 Sep;4(9):898. doi: 10.1016/j.oret.2020.04.008.
Pathophysiology and management of enteric hyperoxaluria.
Joly PF.
Clin Res Hepatol Gastroenterol. 2024 Jun;48(6):102359. doi: 10.1016/j.clinre.2024.102359. Epub 2024 May 10.
Hyperoxaluric calcium nephrolithiasis.
Asplin JR.
Endocrinol Metab Clin North Am. 2002 Dec;31(4):927-49. doi: 10.1016/s0889-8529(02)00030-0.
Primary Hyperoxaluria.
Jiang D, Geng H.
N Engl J Med. 2017 Apr 13;376(15):e33. doi: 10.1056/NEJMicm1609986.
The primary hyperoxalurias.
Leumann E, Hoppe B.
J Am Soc Nephrol. 2001 Sep;12(9):1986-1993. doi: 10.1681/ASN.V1291986.
Hyperoxaluria: Diagnosis and Treatment.
Cunneely OP, Camargo Maluf F, Fargue S, Knight J, Assimos DG, Wood KD.
Urol Clin North Am. 2025 Aug;52(3):315-327. doi: 10.1016/j.ucl.2025.04.012. Epub 2025 May 26.
